Sugiyama K, Yonemura Y, Takamura H, Miwa K, Miyazaki I
Dept. of Surgery II, School of Medicine, Kanazawa University.
Gan To Kagaku Ryoho. 1993 Apr;20(6):796-8.
In vitro labelling index (L.I.) of bromodeoxyuridine (BrdU) was evaluated as a preoperative predictor of gastric cancer development. Biopsy specimens were obtained endoscopically from 187 gastric cancer patients preoperatively. Specimens were incubated in RPMI containing BrdU under carbogen gas at 3 times atmospheric pressure. They were fixed and embedded in paraffin. After slicing and dewaxing, they were denatured in 2N HCl. Then BrdU were stained by ABC method and labelling index was calculated. Patients with L.I. more than 10% had a significantly higher risk of lymph node involvement (p < 0.001) and venous invasion (p < 0.05). Those with L.I. more than 20% had a significantly higher risk of liver metastasis (p < 0.01), while patients with L.I. more than 25% had a significantly higher risk of submucosal invasion (p < 0.01). In conclusion in vitro BrdU labelling is a technique available as a preoperative predictor of node involvement, venous invasion, submucosal invasion and prognosis in gastric cancer.
评估溴脱氧尿苷（BrdU）的体外标记指数（L.I.）作为胃癌发展的术前预测指标。术前通过内镜从187例胃癌患者获取活检标本。标本在含BrdU的RPMI中于3倍大气压的二氧化碳气体下孵育。将其固定并包埋于石蜡中。切片和脱蜡后，在2N盐酸中变性。然后用ABC法对BrdU进行染色并计算标记指数。标记指数大于10%的患者发生淋巴结转移（p<0.001）和静脉侵犯（p<0.05）的风险显著更高。标记指数大于20%的患者发生肝转移（p<0.01）的风险显著更高，而标记指数大于25%的患者发生黏膜下侵犯（p<0.01）的风险显著更高。总之，体外BrdU标记是一种可作为胃癌淋巴结转移、静脉侵犯、黏膜下侵犯及预后的术前预测指标的技术。
